Figure 2.

Augmentation of gadolinium-based contrast agent-induced dermal pathology by experimental diabetes. A: gadolinium-based contrast agent treatment reproducibly induced fibronectin expression and CD163, a marker of alternatively activated macrophages (5). B: experimental diabetes and gadolinium-based contrast agent treatment-induced infiltration of CD45RO-positive fibrocytes and increased 3-nitrotyrosine in the dermis. Immunofluorescence was performed on paraffin-embedded skin. Calibration bars = 0.05 mm. C: experimental diabetes and gadolinium-based contrast agent treatment increased oxidative stress in the skin. Dihydroethidium (DHE) was used with confocal microscopy. Original magnification: ×200. STZ, streptozotocin.